Abstract
Any technical object is defined by a structure and certain related properties, together with a function and a way of making it. A biological object is thus a biochemical structure, either organic or organically based, which possesses one or more biological properties (recognition, structure, transformation, etc.), which carries out a specific function, and which is produced by a biological process. A biological nano-object is a biological object with nanometric dimensions, from which we understand that it is a macromolecule or an assembly of such (diameter of a hemoglobin molecule 5.5 nm). By learning to understand and manipulate the enzymes that produce these macromolecules, biotechnology can today create or sculpt biological nanoobjects using fabrication processes that closely resemble natural mechanisms of synthesis, but which do not require the presence of a living being. Although these activities are recent and still somewhat limited, our mastery of the living tool box has already produced some entities with industrial prospects, including some artificial nano-objects with quite remarkable properties, unknown in nature. Among the biological macromolecules, the nucleic acids play a central role beecause they define both the species and the individual and provide the chemical support for heredity. They are also the only biological molecules we are able to reproduce identically by a simple and well understood enzyme mechanism, viz., the polymerase chain reaction (PCR) (see Chap. 15), which lends itself particularly well to mass production. The nucleic acids feature amongst the most widely used compounds in biology at the current time, e.g., as probes, amplification initiator, etc., as attested by the present market for oligonucleotides (short sequences of nucleic acids): 340 million dollars in 2003, with a predicted 776 million dollars in 2010. However, the use of nucleic acids is generally based on the canonical Watson–Crick pairing of nuclear bases, whose sequence encodes genetic information, while their wealth of structural potential remains virtually unexploited. In contrast, natural evolution has selected many RNA for their catalytic activities or for their ability to interact with proteins or other classes of molecules.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dobzhansky, T.: Nothing in biology makes sense except in the light of evolution, The American Biology Teacher 35, 125–129 (1973)
Darwin, C.: The Origin of Species, Penguin, London (1968)
Luchetta, P., Maurel, M.-C., Higuet, D., Vervoort, M.: Evolution moléculaire: Cours et questions de révisions, Dunod, Collection Sciences Sup (2005)
Mayr, E.: The Growth of Biological Thought, Harvard University Press, MA (1982)
Hermann, T., Patel, D.J.: Stitching together RNA tertiary architectures, J. Mol. Biol. 294, 829–849 (1999)
Cate, J.H., Gooding, A.R., Podell, E., Zhou, K., Golden, B.L., Szewczak, A.A., et al.: RNA tertiary structure mediation by adenosine platforms [see comments], Science 273, 1696–1699 (1996)
Laspia, M.F., Rice, A.P., Mathews, M.B.: HIV-I Tat protein increases transcriptional initiation and stabilizes elongation, Cell 59, 283–292 (1989)
Hermann, T., Patel, D.J.: Adaptive recognition by nucleic acid aptamers, Science 287, 820–825 (2000)
Ghosh, G., Huang, D.B., Huxford, T.: Molecular mimicry of the NF-κB DNA target site by a selected RNA aptamer, Curr. Opin. Struct. Biol. 14, 21–27 (2004)
Oliphant, A.R., Struhl, K.: The use of random-sequence oligonucleotides for determining consensus sequences, Methods Enzymol. 155, 568–582 (1987)
Oliphant, A.R., Brandl, C.J., Struhl, K.: Defining the sequence specificity of DNA-binding proteins by selecting binding sites from random-sequence oligonucleotides: Analysis of yeast GCN4 protein, Mol. Cell. Biol. 9, 2944–2949 (1989)
Kinzler, K.W., Vogelstein, B.: Whole genome PCR: Application to the identification of sequences bound by gene regulatory proteins, Nucleic Acids Res. 17, 3645–3653 (1989)
Ellington, A.D., Szostak, J.W.: In vitro selection of RNA molecules that bind specific ligands, Nature 346, 818–822 (1990)
Robertson, D.L., Joyce, G.F.: Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA, Nature 344, 467–468 (1990)
Tuerk, C., Gold, L.: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science 249, 505–510 (1990)
Green, R., Ellington, A.D., Szostak, J.W.: In vitro genetic analysis of the tetrahymena self-splicing intron, Nature 347, 406–408 (1990)
Thiesen, H.J., Bach, C.: Target Detection Assay (TDA): A versatile procedure to determine DNA binding sites as demonstrated on SP1 protein, Nucleic Acids Res. 18, 3203–3209 (1990)
Blackwell, T.K., Kretzner, L., Blackwood, E.M., Eisenman, R.N., Weintraub, H.: Sequence-specific DNA binding by the c-Myc protein, Science 250, 1149–1151 (1990)
Blackwell, T.K., Weintraub, H.: Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection, Science 250, 1104–1110 (1990)
Pollock, R., Treisman, R.: A sensitive method for the determination of protein–DNA binding specificities, Nucleic Acids Res. 18, 6197–6204 (1990)
Joyce, G.F.: Directed molecular evolution, Sci. Am. 267 (6), 48–55 (1992)
Osborne, S.E., Matsumura, I., Ellington, A.D.: Aptamers as therapeutic and diagnostic reagents: Problems and prospects, Curr. Opin. Chem. Biol. 1, 5–9 (1997)
Gold, L., Polisky, B., Uhlenbeck, O., Yarus, M.: Diversity of oligonucleotide functions, Annu. Rev. Biochem. 64, 763–797 (1995)
Fitzwater, T., Polisky, B.: A SELEX primer, Methods Enzymol. 267, 275–301 (1996)
Cox, J.C., Rudolph, P., Ellington, A.D.: Automated RNA selection, Biotechnol. Prog. 14, 845–850 (1998)
Brody, E.N., Gold, L.: Aptamers as therapeutic and diagnostic agents, J. Biotechnol. 74, 5–13 (2000)
Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., et al.: Direct in vitro selection of a 2′-O-methyl aptamer to VEGF, Chem. Biol. 12, 25–33 (2005)
Green, L.S., Kirschenheuter, G.P., Charlton, J., Guidot, D.M., Repine, J.M.: Nuclease resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor, Chem. Biol. 2, 683–695 (1995)
Pagratis, N., Bell, C., Chang, Y., Jennings, S., Fitzwater, T., Jellinek, D., et al.: Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor, Nature Biotech. 15, 68–73 (1997)
Micklefield, J.: Backbone modification of nucleic acids: Synthesis, structure and therapeutic applications, Curr. Med. Chem. 8, 1157–1179 (2001)
Latham, J.A., Johnson, R., Toole, J.J.: The application of a modified nucleotide in aptamer selection: A novel thrombin aptamer containing 5-(1-pentynyl)-2′-deoxyurudine, Nucleic Acid Res. 22, 2817–2822 (1994)
Vater, A., Klussmann, S.: Toward third-generation aptamers: Spiegelmers and their therapeutic prospects, Curr. Opin. Drug Discov. Devel. 6, 253–261 (2003)
Kumar, P.K.R., Ellington, A.D.: Artificial evolution and natural ribozymes, FASEB J. 9, 1183–1195 (1995)
Lehman, N., Joyce, G.F.: Evolution in vitro of an RNA enzyme with altered metal dependence, Nature 361, 182–185 (1993)
Tsang, J., Joyce, G.F.: Specialization of the DNA-cleaving activity of a group I ribozyme through in vitro evolution, J. Mol. Biol. 262, 31–42 (1996)
Bartel, D.P., Szostak, J.W.: Isolation of new ribozymes from a large pool of random sequences, Science 261, 1411–1418 (1993)
Ekland, E.H., Bartel, D.P.: RNA-catalysed RNA polymerization using nucleoside triphosphates, Nature 383, 192 (1996)
Deng, Q., German, I., Buchanan, D., Kennedy, R.T.: Retention and separation of adenosine and analogues by affinity chromatography with an aptamer stationary phase, Anal. Chem. 73, 5415–5421 (2001)
Romig, T.S., Bell, C., Drolet, D.W.: Aptamer affinity chromatography: Combinatorial chemistry applied to protein purification, J. Chromatogr. B Biomed. Sci. Appl. 731, 275–284 (1999)
Michaud, M., Jourdan, E., Villet, A., Ravel, A., Grosset, C., Peyrin, E.: A DNA aptamer as a new target-specific chiral selector for HPLC, J. Am. Chem. Soc. 125, 8672–8679 (2003)
Dick, L.W., Jr., McGown, L.B.: Aptamer-enhanced laser desorption/ionization for affinity mass spectrometry, Anal. Chem. 76, 3037–3041 (2004)
Blank, M., Weinschenk, T., Priemer, M., Schluesener, H.: Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels: Selective targeting of endothelial regulatory protein pigpen, J. Biol. Chem. 276, 16464–16468 (2001)
Daniels, D.A., Chen, H., Hicke, B.J., Swiderek, K.M., Gold, L.: A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment, Proc. Natl. Acad. Sci. USA 100, 15416–15421 (2003)
Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gustafsdottir, S.M., et al.: Protein detection using proximity-dependent DNA ligation assays, Nat. Biotechnol. 20, 473–477 (2002)
Wang, X.L., Li, F., Su, Y.H., Sun, X., Li, X.B., Schluesener, H.J., et al.: Ultrasensitive detection of protein using an aptamer-based exonuclease protection assay, Anal. Chem. 76, 5605–5610 (2004)
Jhaveri, S., Rajendran, M., Ellington, A.D.: In vitro selection of signaling aptamers, Nat. Biotechnol. 18, 1293–1297 (2000)
Hamaguchi, N., Ellington, A., Stanton, M.: Aptamer beacons for the direct detection of proteins, Anal. Biochem. 294, 126–131 (2001)
Petach, H., Gold, L.: Dimensionality is the issue: Use of photoaptamers in protein microarrays, Curr. Opin. Biotechnol. 13, 309–314 (2002)
Smith, D., Collins, B.D., Heil, J., Koch, T.H.: Sensitivity and specificity of photoaptamer probes, Mol. Cell. Proteomics 2, 11–18 (2003)
Charlton, J., Sennello, J., Smith, D.: In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase, Chem. Biol. 4, 809–816 (1997)
Tavitian, B.: In vivo imaging with oligonucleotides for diagnosis and drug development, Gut 52, Suppl. 4, 40–47 (2003)
Werstuck, G., Green, M.R.: Controlling gene expression in living cells through small molecule–RNA interactions, Science 282, 296-298 (1998)
Good, P.D., Krikos, A.J., Li, S.X., Bertrand, E., Lee, N.S., Giver, L., et al.: Expression of small, therapeutic RNAs in human cell nuclei, Gene. Ther. 4, 45–54 (1997)
Thomas, M., Chedin, S., Carles, C., Riva, M., Famulok, M., Sentenac, A.: Selective targeting and inhibition of yeast RNA polymerase II by RNA aptamers, J. Biol. Chem. 272, 27980–27986 (1997)
Shi, H., Hoffman, B.E., Lis, J.T.: RNA aptamers as effective protein antagonists in a multicellular organism, Proc. Natl. Acad. Sci. USA 96, 10033–10038 (1999)
Vuyisich, M., Beal, P.A.: Controlling protein activity with ligand-regulated RNA aptamers, Chem. Biol. 9, 907–913 (2002)
Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., et al.: Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase, PLoS Biol. 3, 123 (2005)
Bock, L.C., Griffin, L.C., Latham, J.A., Vermaas, E.H., Toole, J.J.: Selection of single-stranded DNA molecules that bind and inhibit human thrombin, Nature 355, 564–566 (1992)
Kelly, J.A., Feigon, J., Yeates, T.O.: Reconciliation of the X-ray NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG), J. of Biochemistry 256, 417–422 (1996)
Griffin, L.C., Tidmarsh, G.F., Bock, L.C., Toole, J.J., Leung, L.L.: In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits, Blood 81, 3271–3276 (1993)
Rusconi, C.P., Scardino, E., Layzer, J., Pitoc, G.A., Ortel, T.L., Monroe, D., et al.: RNA aptamers as reversible antagonists of coagulation factor IXa, Nature 419, 90–94 (2002)
Rusconi, C.P., Roberts, J.D., Pitoc, G.A., Nimjee, S.M., White, R.R., Quick, G., Jr., et al.: Antidote-mediated control of an anticoagulant aptamer in vivo, Nat. Biotechnol. 22, 1423–1428 (2004)
Hicke, B.J., Stephens, A.W.: Escort aptamers: A delivery service for diagnosis and therapy, J. Clin. Invest. 106, 923–928 (2000)
Lin, Y., Qiu, Q., Gill, S.C., Jayasena, S.D.: Modified RNA sequence pools for in vitro selection, Nucleic Acids Res. 22, 5229–5234 (1994)
Lin, Y., Padmapriya, A., Morden, K.M., Jayasena, S.D.: Peptide conjugation to an in vitro-selected DNA ligand improves enzyme inhibition, Proc. Natl. Acad. Sci. USA 92, 11044–11048 (1995)
Pestourie, C., Tavitian, B., Ducongé, F.: Aptamers against extracellular targets for in vivo applications, Biochimie 87, 921–930 (2005)
Jenison, R.D., Gill, S.C., Pardi, A., Polisky, B.: High-resolution molecular discrimination by RNA, Science 263, 1425–1429 (1994)
Cerchia, L., Hamm, J., Libri, D., Tavitian, B., de Franciscis, V.: Nucleic acid aptamers in cancer medicine, FEBS Lett. 528, 12–16 (2002)
Bittker, J.A., Le, B.V., Liu, D.R.: Nucleic acid evolution and minimization by nonhomologous random recombination, Nat. Biotechnol. 20, 1024–1029 (2002)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chauveau, F., Pestourie, C., Ducongé, F., Tavitian, B. (2009). Aptamer Selection by Darwinian Evolution. In: Boisseau, P., Houdy, P., Lahmani, M. (eds) Nanoscience. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88633-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-88633-4_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-88632-7
Online ISBN: 978-3-540-88633-4
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)